Bellevue

Team

The team of experienced biotech specialists has established an enviable track record in identifying and managing investment opportunities in the biotech sector.

Dr. Daniel Koller

Head Investment Management
read more

Dr. Daniel Koller

Head Investment Management
« With an estimated growth of more than 10% a year, biotech is one of the most attractive sectors today »
Dr. Daniel Koller has been with Bellevue Asset Management since 2004 as a Portfolio Manager and was appointed Head of Investment Management Team BB Biotech AG in 2010. From 2001–2004 he was an investment manager at equity4life Asset Management AG and from 2000–2001 an equity analyst at UBS Warburg. He studied biochemistry at the Swiss Federal Institute of Technology in Zurich (ETH) and earned his doctorate in biotechnology at the ETH and Cytos Biotechnology AG, Zurich.

Felicia Flanigan

Investment Management Team
read more

Felicia Flanigan

Investment Management Team
« Our investment strategy is focused on innovative drugs and therapies that offer sound value to healthcare systems »
Felicia Flanigan has been with Bellevue Asset Management as a Portfolio Manager since 2004. From 1999–2004 she was a biotech equity analyst at Adams, Harkness & Hill; from 1991–1999 a biotech equity analyst at SG Cowen. Felicia Flanigan holds an MBA from Suffolk University, Boston, and a BA in Communications from Boston College.

Dallas Webb

Investment Management Team
read more

Dallas Webb

Investment Management Team
« Takeover activity in the sector will fuel significant valuation gains over a mid- and long-term horizon »
Dallas Webb has been with Bellevue Asset Management as a Portfolio Manager since 2006. From 2004–2006 he served as Senior Vice President and Equity Analyst at Stanford Group Company and held the same role at Sterling Financial Investment Group from 2003–2004. Prior to that, he was an equity analyst at Adams, Harkness & Hill. Dallas Webb has an MBA from Texas Christian University in Fort Worth, Texas, and a Bachelor of Science in Microbiology and Zoology from Louisiana State University.

Dr. Christian Koch

Investment Management Team
read more

Dr. Christian Koch

Investment Management Team
« Every second drug approved by regulators today originated from the lab of a biotech company »
Dr. Christian Koch has been with Bellevue Asset Management as a Portfolio Manager since 2014. From 2013–2014 he was a sell-side pharma & biotech equity analyst at Bank am Bellevue in Küsnacht and from 2010–2013 a research associate at the Institute of Pharmaceutical Sciences, ETH Zurich. He holds a Ph.D. in Chemoinformatics & Computational Drug Design from ETH Zurich and an MS in Bioinformatics from Goethe University in Frankfurt.

Its academic expertise, many years of experience and collaboration, and a broad interest in all areas of medicine, biochemistry, and economics ensure an inspiring and constructive interdisciplinary dialogue within the team and with the Board of Directors as well as with external experts such as physicians and analysts.

Dr. Stephen Taubenfeld

Investment Management Team
read more

Dr. Stephen Taubenfeld

Investment Management Team
« Our investment portfolio is distinguished by a well-balanced risk/reward profile »
Dr. Stephen Taubenfeld has been with Bellevue Asset Management as a Portfolio Manager since 2013. From 2009–2013 he was Senior Analyst at Iguana Healthcare Partners, of which he was a founding partner. From 2008–2009 he was a consultant with Merlin BioMed Group and from 2004–2008 he was M.D./Ph.D. Fellow in Neuroscience at Mount Sinai Hospital, New York. He holds an M.D. and Ph.D. in Neuroscience from Brown University School of Medicine.

Dr. Maurizio Bernasconi

Investment Management Team
read more

Dr. Maurizio Bernasconi

Investment Management Team
« Biotech is driving innovation in medicine »

Dr. Maurizio Bernasconi has been with Bellevue Asset Management as a Portfolio Manager since 2017. He joined Bank am Bellevue as a research analyst for pharma and biotech sector in 2014, prior to which has worked as a chemist for SIGA Manufacturing, Ruswil. From 2009–2013 he doctored in organic chemistry at the University of Basel. Maurizio Bernasconi holds an Bachelor and Master in chemistry from ETH Zurich and a Ph.D. from the University of Basel and an MBA in International Healthcare Management from the Frankfurt School of Finance.

Dr. Samuel Croset

Investment Management Team
read more

Dr. Samuel Croset

Investment Management Team
« Substantially improved computational approaches in drug screening, identification and selection all the way to smarter and adaptive clinical trial programs are contributing to an acceleration of the innovation cycle »

Dr. Samuel Croset joined Bellevue Asset Management as a Portfolio Manager and Digital Transformation Lead in 2020. He previously worked for Roivant Sciences from 2018-2020 as data scientist supporting investment decisions in drug projects as well as leading a team focused on the analysis of real-world data. Prior to that, he started his professional career at Roche as data scientist in the research department (2014-2018). Samuel holds a Ph.D. in Bioinformatics from the University of Cambridge, a MS in Bioinformatics and a MS in Biochemistry from the University of Geneva.

Dr. Silvia Siegfried-Schanz

Investor Relations
read more

Dr. Silvia Siegfried-Schanz

Investor Relations
  • Since 2012 with Bellevue Asset Management as Director Investor Relations for the investment company BB Biotech AG
  • 2011 – 2012 UBS Wealth Management, Buy-side Financial Analyst, Global Healthcare
  • 2008 – 2011 Vontobel Investment Banking, Sell-side Financial Analyst, Pharmaceuticals and Biotechnology
  • Certified International Investment Analyst (CIIA)
  • PhD / doctorate in Biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich
  • Master in Biochemistry, minor in Business Administration of the University Freiburg

Claude Mikkelsen

Investor Relations
read more

Claude Mikkelsen

Investor Relations
  • Since 2012 with Bellevue Asset Management as Director Investor Relations for the investment company  BB Biotech AG
  • 2011-2012 Finance Director (interim), Nordic Region at Ecron Acunova A/S
  • 2009-2012 Senior Consultant, CMI Consulting
  • 2005-2009 Senior Vice President, Finance & Investor Relations at Pharmexa A/S
  • 2003-2005 Legal Consultant at Dako A/S
  • 2001-2003 Consultant at Deloitte
  • Master’s degree in Economy and Law, Aalborg University

    Maria-Grazia Iten-Alderuccio

    Investor Relations
    read more

    Maria-Grazia Iten-Alderuccio

    Investor Relations
    • Since 2007 with Bellevue Asset Management as Director Investor Relations BB Biotech AG
    • 2004–2007 Citco Fund Advisors, senior relationship manager
    • Master's degree in Linguistics from the University of Lausanne and Università degli Studi di Firenze, Italy